• News
    • Latest news
    • News search
    • Health
    • Finance
    • Food
    • Career news
    • Content series
    • Try Devex Pro
  • Jobs
    • Job search
    • Post a job
    • Employer search
    • CV Writing
    • Upcoming career events
    • Try Career Account
  • Funding
    • Funding search
    • Funding news
  • Talent
    • Candidate search
    • Devex Talent Solutions
  • Events
    • Upcoming and past events
    • Partner on an event
  • Post a job
  • About
      • About us
      • Membership
      • Newsletters
      • Advertising partnerships
      • Devex Talent Solutions
      • Contact us
Join DevexSign in
Join DevexSign in

News

  • Latest news
  • News search
  • Health
  • Finance
  • Food
  • Career news
  • Content series
  • Try Devex Pro

Jobs

  • Job search
  • Post a job
  • Employer search
  • CV Writing
  • Upcoming career events
  • Try Career Account

Funding

  • Funding search
  • Funding news

Talent

  • Candidate search
  • Devex Talent Solutions

Events

  • Upcoming and past events
  • Partner on an event
Post a job

About

  • About us
  • Membership
  • Newsletters
  • Advertising partnerships
  • Devex Talent Solutions
  • Contact us
  • My Devex
  • Update my profile % complete
  • Account & privacy settings
  • My saved jobs
  • Manage newsletters
  • Support
  • Sign out
Latest newsNews searchHealthFinanceFoodCareer newsContent seriesTry Devex Pro
    • News
    • COVID-19

    African nations struggle to access range of COVID-19 drugs, says WHO

    Some drugs are prohibitively expensive and in limited supply.

    By Sara Jerving // 20 January 2022
    A pharmacist displays a box of immunosuppressive drug tocilizumab. Photo by: Pascal Rossignol / Reuters

    African nations will struggle to gain access to the full range of COVID-19 therapeutics because of high cost and limited supplies, according to the World Health Organization.  

    “The deep inequity that left Africa at the back of the queue for vaccines must not be repeated with life saving treatments,” said Dr. Matshidiso Moeti, director of WHO’s regional office for Africa, during a press conference Thursday.

    Sign up for Devex CheckUp
    The must-read weekly newsletter for exclusive global health news and insider insights.

    Expensive and limited: Patients with severe forms of the virus are currently treated with corticosteroids, which are largely available and affordable, and medical oxygen supplies, which are limited in many settings.

    But other treatments are more pricey. Casirivimab/imdevimab, for example, which can help people from advancing to more severe disease, costs between $550 to $1,220 for a single dose, Moeti said.  

    Even with efforts to make these drugs available for generic production with the Medicines Patent Pool, they will still be produced in limited quantities in the immediate future, said Harley Feldbaum, head of strategy and policy at The Global Fund to Fight AIDS, Tuberculosis and Malaria.

    “The challenge is they will be in short supply, they are in high global demand, and wealthy countries are acting very quickly to secure those supplies,” he said.

    “We need more financing to be able to deliver these new therapeutic products,” he added.

    Equitable access: WHO has approved 11 therapeutics to treat COVID-19. Following negotiations with pharmaceutical company Roche, the agency shipped vials of tocilizumab, an immunosuppressive drug, to Cape Verde and Uganda. Burkina Faso, Ghana, and Tanzania are also expecting shipments. In July, Médecins Sans Frontières warned that the drug was unaffordable.

    “We will have a situation throughout 2022 where these new products will need to be allocated under WHO’s leadership to countries with … the highest number of severe and critical cases so these scarce products have the most impact,” Feldbaum said.

    But in terms of preventing wealthy countries from hoarding these drugs, WHO “does not have the power to compel countries to act in one way or another,” he said.

    • Global Health
    • Private Sector
    • Trade & Policy
    • WHO
    Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).

    About the author

    • Sara Jerving

      Sara Jervingsarajerving

      Sara Jerving is a Senior Reporter at Devex, where she covers global health. Her work has appeared in The New York Times, the Los Angeles Times, The Wall Street Journal, VICE News, and Bloomberg News among others. Sara holds a master's degree from Columbia University Graduate School of Journalism where she was a Lorana Sullivan fellow. She was a finalist for One World Media's Digital Media Award in 2021; a finalist for the Livingston Award for Young Journalists in 2018; and she was part of a VICE News Tonight on HBO team that received an Emmy nomination in 2018. She received the Philip Greer Memorial Award from Columbia University Graduate School of Journalism in 2014.

    Search for articles

    Related Stories

    Global healthAmid global health funding cuts, Africa is struggling with opioid abuse

    Amid global health funding cuts, Africa is struggling with opioid abuse

    Global HealthHow unregulated antibiotics are fueling drug-resistant UTIs

    How unregulated antibiotics are fueling drug-resistant UTIs

    Global healthUSAID funding cuts jeopardize breakthrough drugs and research

    USAID funding cuts jeopardize breakthrough drugs and research

    The Trump effectWhat's included in the USAID global health waiver

    What's included in the USAID global health waiver

    Most Read

    • 1
      How low-emissions livestock are transforming dairy farming in Africa
    • 2
      Opinion: Mobile credit, savings, and insurance can drive financial health
    • 3
      Opinion: India’s bold leadership in turning the tide for TB
    • 4
      USAID's humanitarian bureau is under pressure and overstretched
    • 5
      The UN's changing of the guard
    • News
    • Jobs
    • Funding
    • Talent
    • Events

    Devex is the media platform for the global development community.

    A social enterprise, we connect and inform over 1.3 million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people. We invite you to join us.

    • About us
    • Membership
    • Newsletters
    • Advertising partnerships
    • Devex Talent Solutions
    • Post a job
    • Careers at Devex
    • Contact us
    © Copyright 2000 - 2025 Devex|User Agreement|Privacy Statement